Endocrinology Today—May 12, 2026

This week’s Endocrinology update highlights regulatory access changes, diabetes research advances, osteoporosis findings, and evolving endocrine care strategies.

In Today’s Newsletter

Dive deeper

🩺 UAE diabetes registry shows female cases exceeded male cases [1] [UAE • 09 May 2026]

https://gulfnews.com/uae/health/uae-data-shows-female-diabetes-cases-surpassed-males-in-2025-1.500534696
Context: Emirates Health Services reported 2025 diabetes registrations across EHS primary healthcare centres.
Key point: Registered female diabetes patients exceeded male patients, and Sharjah recorded the highest EHS centre count.
Implication: May expand screening, initiation, and follow-up at scale.

🌸 FDA menopause hormone labeling change reframes HRT conversations [2] [US • 10 May 2026]

https://creators.yahoo.com/lifestyle/story/the-fda-recently-removed-decades-old-warnings-from-menopause-hormones–heres-what-an-obgyn-wants-you-to-know-132417814.html
Context: Yahoo cited an OB/GYN discussing FDA menopause hormone labeling changes that took effect in February 2026.
Key point: The article says removal of older warnings is shifting HRT discussions toward individualized risk-benefit conversations.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧬 Biomea Fusion icovamenib selected for ADA 2026 late-breaker posters [3] [US • 06 May 2026]

http://biospace.com/press-releases/biomea-fusion-announces-poster-presentations-of-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions
Context: Biomea Fusion will present three late-breaking posters at ADA 2026 in New Orleans on 07 Jun 2026.
Key point: Icovamenib (Biomea Fusion; oral menin inhibitor) posters cover COVALENT-111, COVALENT-112, and metabolic-health mechanisms.
Implication: Signals pipeline investment and modality expansion.

🦴 TGF-β inhibition may enhance anti-sclerostin osteoporosis treatment [4] [South Korea • 08 May 2026]

https://bioengineer.org/inhibiting-tgf-%ce%b2-signaling-could-enhance-osteoporosis-treatment-effectiveness/
Context: Seoul National University researchers used spatial transcriptomics, lineage tracing, organoids, and mouse models.
Key point: The article says TGF-β signaling maintains osteoblast quiescence, and blockade enhanced anti-sclerostin effects in preclinical models.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Liver fat linked to abnormal glucagon response in early type 2 diabetes [5] [Germany • 10 May 2026]

https://www.news-medical.net/news/20260510/Liver-fat-may-disrupt-post-meal-glucagon-control-in-early-type-2-diabetes.aspx
Context: Diabetes Care study analyzed 100 German Diabetes Study adults, including newly diagnosed T2D and matched controls.
Key point: MASLD and higher liver fat were associated with elevated fasting and post-meal glucagon in newly diagnosed T2D.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

⚕️ CRENESSITY expert guidance published for glucocorticoid reduction [6] [US • 06 May 2026]

https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-publication-of-expert-recommendations-for-glucocorticoid-dose-reduction-after-initiating-crenessity-crinecerfont-for-the-treatment-of-classic-congenital-adrenal-hyperplasia-302763404.html
Context: Neurocrine Biosciences announced peer-reviewed pediatric and adult guidance in The Journal of Clinical Endocrinology & Metabolism.
Key point: Expert algorithms address supervised glucocorticoid reduction after CRENESSITY (crinecerfont) initiation in classic CAH.
Implication: May influence prescriber choice and payer reviews pending full data.

📌 Korea reimburses Novo Nordisk’s weekly growth hormone Sogroya [7] [South Korea • 06 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31552
Context: Novo Nordisk Pharma Korea said national health insurance coverage for Sogroya began under a Ministry of Health and Welfare notice.
Key point: Eligible children and adults with growth hormone deficiency can access once-weekly Sogroya (somapacitan) with reimbursement.
Implication: Introduces competition that may affect pricing and formulary access.

🦶 Apollo introduces CERAMENT G for diabetic and complex bone infections [8] [India • 05 May 2026]

https://www.prnewswire.com/news-releases/apollo-hospitals-introduces-first-of-its-kind-advanced-bone-regeneration-solution-for-diabetic-and-complex-bone-infections-302762699.html
Context: Apollo Hospitals introduced BONESUPPORT’s CERAMENT G in India with clinical training at Jubilee Hills, Hyderabad.
Key point: CERAMENT G is an injectable antibiotic-eluting bone graft substitute for local infection control and bone regeneration.
Implication: May expand screening, initiation, and follow-up at scale.

Why It Matters

Diabetes care remains a central systems issue, from UAE registry monitoring to Biomea’s beta-cell-focused drug program and glucagon research in MASLD.
Endocrine access shifted this week, with Korea reimbursement for once-weekly Sogroya and expert guidance supporting CRENESSITY use in classic CAH.
Bone health stories spanned preclinical osteoporosis biology and India’s rollout of a local antibiotic-eluting bone graft substitute.
Menopause hormone therapy remains a fast-moving clinical conversation, with source emphasis on individualized risk assessment.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What did Emirates Health Services report about diabetes in 2025?

EHS data cited by Gulf News showed female diabetes registrations exceeded male registrations across EHS primary healthcare centres in 2025. Sharjah had the highest registered count among EHS centres. [1]

What is Biomea Fusion presenting on icovamenib at ADA 2026?

Biomea said three late-breaking posters will cover icovamenib in type 2 diabetes on background GLP-1 therapy, type 1 diabetes endogenous insulin secretion, and metabolic-health mechanisms. [3]

What did the Diabetes Care study suggest about MASLD and glucagon?

The News-Medical summary said MASLD and liver fat were associated with higher fasting and early post-meal glucagon in newly diagnosed type 2 diabetes. The study was cross-sectional, so causality was not established. [5]

What is CRENESSITY guidance meant to help clinicians do?

Neurocrine said the expert publications provide pediatric and adult algorithms for reducing supraphysiologic glucocorticoid doses after CRENESSITY initiation in classic CAH, when clinically appropriate. [6]

Who may benefit from Korea reimbursement for Sogroya?

Korea BioMed reported that eligible children and adults with growth hormone deficiency can now receive national insurance coverage for Novo Nordisk’s once-weekly Sogroya. Criteria differ by age and diagnosis pathway. [7]

What is CERAMENT G being used for at Apollo Hospitals?

Apollo described CERAMENT G as an injectable antibiotic-eluting bone graft substitute for diabetic foot infections, trauma, and chronic osteomyelitis, aiming to support infection control and bone regeneration. [8]

Entities / Keywords

Emirates Health Services, EHS, UAE diabetes registry, Sharjah, Ras Al Khaimah, Fujairah
Hormone replacement therapy, HRT, menopause hormone therapy, FDA labeling, Women’s Health Initiative, WHI
Biomea Fusion, icovamenib, oral menin inhibitor, COVALENT-111, COVALENT-112, ADA 2026
TGF-β signaling, anti-sclerostin therapy, osteoblast quiescence, osteoporosis, Seoul National University
Type 2 diabetes, T2D, MASLD, glucagon, German Diabetes Study, Diabetes Care
Neurocrine Biosciences, CRENESSITY, crinecerfont, classic CAH, glucocorticoid reduction, CAHtalyst
Novo Nordisk, Sogroya, somapacitan, growth hormone deficiency, Korea reimbursement
Apollo Hospitals, BONESUPPORT, CERAMENT G, diabetic foot infection, chronic osteomyelitis, bone regeneration